HU186180B - Process for producing 3,7a-diaza-cyclohepta-bracket-j,k-bracket closed-fluorene derivatives and pharmaceutical compositions containing them - Google Patents
Process for producing 3,7a-diaza-cyclohepta-bracket-j,k-bracket closed-fluorene derivatives and pharmaceutical compositions containing them Download PDFInfo
- Publication number
- HU186180B HU186180B HU828374A HU837482A HU186180B HU 186180 B HU186180 B HU 186180B HU 828374 A HU828374 A HU 828374A HU 837482 A HU837482 A HU 837482A HU 186180 B HU186180 B HU 186180B
- Authority
- HU
- Hungary
- Prior art keywords
- formula
- compound
- hydrogen
- pharmaceutically acceptable
- compounds
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 35
- 239000001257 hydrogen Substances 0.000 claims abstract description 18
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 18
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 10
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 9
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims abstract description 7
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims abstract description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 8
- 239000002253 acid Substances 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- 239000012280 lithium aluminium hydride Substances 0.000 claims description 5
- -1 lithium aluminum hydride Chemical compound 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 150000002431 hydrogen Chemical class 0.000 claims description 4
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 3
- 208000020401 Depressive disease Diseases 0.000 claims description 2
- 208000003443 Unconsciousness Diseases 0.000 claims description 2
- 238000009903 catalytic hydrogenation reaction Methods 0.000 claims description 2
- 238000007911 parenteral administration Methods 0.000 claims description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims 1
- 206010021143 Hypoxia Diseases 0.000 claims 1
- 150000007513 acids Chemical class 0.000 claims 1
- 230000032683 aging Effects 0.000 claims 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims 1
- 229910052782 aluminium Inorganic materials 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 239000000460 chlorine Chemical group 0.000 abstract description 4
- 230000000496 anti-anoxic effect Effects 0.000 abstract description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 abstract description 2
- 229910052801 chlorine Inorganic materials 0.000 abstract description 2
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 8
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- NIHNNTQXNPWCJQ-UHFFFAOYSA-N fluorene Chemical compound C1=CC=C2CC3=CC=CC=C3C2=C1 NIHNNTQXNPWCJQ-UHFFFAOYSA-N 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 6
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical class [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 238000010171 animal model Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- HTSGKJQDMSTCGS-UHFFFAOYSA-N 1,4-bis(4-chlorophenyl)-2-(4-methylphenyl)sulfonylbutane-1,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C(C(=O)C=1C=CC(Cl)=CC=1)CC(=O)C1=CC=C(Cl)C=C1 HTSGKJQDMSTCGS-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 206010066296 Cerebral calcification Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- 208000010496 Heart Arrest Diseases 0.000 description 1
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010029897 Obsessive thoughts Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000006264 debenzylation reaction Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 150000002220 fluorenes Chemical class 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000003434 inspiratory effect Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/16—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Neurology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Revetment (AREA)
- Non-Reversible Transmitting Devices (AREA)
- Glass Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8122643A FR2517679A1 (fr) | 1981-12-03 | 1981-12-03 | Derives de diaza-3,7a cyclohepta (j,k) fluorenes, leur preparation et leur application en therapeutique |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HU186180B true HU186180B (en) | 1985-06-28 |
Family
ID=9264634
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU828374A HU186180B (en) | 1981-12-03 | 1982-12-02 | Process for producing 3,7a-diaza-cyclohepta-bracket-j,k-bracket closed-fluorene derivatives and pharmaceutical compositions containing them |
Country Status (18)
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4624954A (en) * | 1985-12-20 | 1986-11-25 | American Home Products Corporation | 6,7,8,9-tetrahydro-10-methylpyrido[1,2-a]indol-9-amines and derivatives thereof, useful for the treatment of cognitive impairments |
| US4665183A (en) * | 1985-12-20 | 1987-05-12 | American Home Products Corp. | Process for preparing 6,7,8,9-tetrahydro-10-methylpyrido[1,2-a]indol-9-amines and derivatives thereof useful for the treatment of cognitive impairments |
| CA2027814C (en) * | 1989-10-20 | 1996-07-30 | Ryuji Ueno | Treatment of hepatobiliary disease with 15-keto-prostaglandin compounds |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DD129791A5 (de) * | 1976-04-13 | 1978-02-08 | Synthelabo | Verfahren zur herstellung von naphtyridinderivaten |
| US4228168A (en) * | 1978-11-22 | 1980-10-14 | Tanabe Seiyaku Co., Ltd. | Azepino [1,2,3-lm]-β-carboline compounds and pharmaceutical composition thereof |
| JPS55161389A (en) * | 1979-06-01 | 1980-12-15 | Ngk Spark Plug Co | Method of connecting porcelain insulator to fitting |
-
1981
- 1981-12-03 FR FR8122643A patent/FR2517679A1/fr active Granted
-
1982
- 1982-11-29 DE DE8282402172T patent/DE3268605D1/de not_active Expired
- 1982-11-29 EP EP82402172A patent/EP0082040B1/fr not_active Expired
- 1982-11-29 AT AT82402172T patent/ATE17485T1/de active
- 1982-12-02 IL IL67400A patent/IL67400A/xx unknown
- 1982-12-02 NO NO824040A patent/NO824040L/no unknown
- 1982-12-02 ES ES517874A patent/ES517874A0/es active Granted
- 1982-12-02 PT PT75925A patent/PT75925B/pt unknown
- 1982-12-02 GR GR69964A patent/GR77848B/el unknown
- 1982-12-02 NZ NZ202688A patent/NZ202688A/en unknown
- 1982-12-02 HU HU828374A patent/HU186180B/hu unknown
- 1982-12-02 DK DK535082A patent/DK535082A/da not_active Application Discontinuation
- 1982-12-02 US US06/446,368 patent/US4503058A/en not_active Expired - Fee Related
- 1982-12-02 CA CA000416847A patent/CA1196329A/en not_active Expired
- 1982-12-02 AU AU91076/82A patent/AU553493B2/en not_active Ceased
- 1982-12-02 ZA ZA828877A patent/ZA828877B/xx unknown
- 1982-12-02 FI FI824155A patent/FI71321C/fi not_active IP Right Cessation
- 1982-12-03 JP JP57213239A patent/JPS58109487A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU553493B2 (en) | 1986-07-17 |
| ZA828877B (en) | 1983-09-28 |
| FI824155L (fi) | 1983-06-04 |
| NZ202688A (en) | 1985-01-31 |
| CA1196329A (en) | 1985-11-05 |
| NO824040L (no) | 1983-06-06 |
| ATE17485T1 (de) | 1986-02-15 |
| GR77848B (enrdf_load_stackoverflow) | 1984-09-25 |
| FI824155A0 (fi) | 1982-12-02 |
| JPS58109487A (ja) | 1983-06-29 |
| DE3268605D1 (en) | 1986-02-27 |
| IL67400A (en) | 1985-07-31 |
| ES8401488A1 (es) | 1983-12-01 |
| PT75925A (fr) | 1983-01-01 |
| DK535082A (da) | 1983-06-04 |
| FI71321B (fi) | 1986-09-09 |
| FI71321C (fi) | 1986-12-19 |
| US4503058A (en) | 1985-03-05 |
| PT75925B (fr) | 1985-12-20 |
| FR2517679A1 (fr) | 1983-06-10 |
| AU9107682A (en) | 1983-06-09 |
| IL67400A0 (en) | 1983-05-15 |
| EP0082040A1 (fr) | 1983-06-22 |
| FR2517679B1 (enrdf_load_stackoverflow) | 1984-01-27 |
| EP0082040B1 (fr) | 1986-01-15 |
| ES517874A0 (es) | 1983-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3783988T2 (de) | Zyklische enolderivate, herstellung und anwendung. | |
| JP2716965B2 (ja) | ピペリジン誘導体を含有する医薬 | |
| EP0363415B1 (en) | Compounds for the treatment of alzheimer's disease | |
| IE47798B1 (en) | Substituted ortho-anisamides,methods of preparing them,compositions containing them and their application as psychotropic agents | |
| CA1066710A (en) | 7-methoxy-6-thiatetracyclines and their preparation | |
| JPS6126996B2 (enrdf_load_stackoverflow) | ||
| US4528289A (en) | Corynantheine derivates, processes for their preparation, and their use | |
| DE69122858T2 (de) | Therapeutische benzazepin verbindungen | |
| DE69411616T2 (de) | Triazolopyridazin-Derivate, ihre Herstellung und Verwendung | |
| HU186180B (en) | Process for producing 3,7a-diaza-cyclohepta-bracket-j,k-bracket closed-fluorene derivatives and pharmaceutical compositions containing them | |
| DE2632118C3 (de) | Apovincaminolester und Verfahren zu deren Herstellung und Arzneimittel | |
| US4451473A (en) | 3,7-Diazabicyclo [3.3.1] nonanes having anti-arrhythmic activity | |
| DE1518452B2 (de) | 4-substituierte 2-benzhydryl-2butanol-derivate und verfahren zu ihrer herstellung | |
| NO794271L (no) | Fremgangsmaate for fremstilling av indol-dioner | |
| AU649302B2 (en) | Tricyclic pyridone derivative | |
| EP0330756B1 (de) | Thienotricyclen zur Behandlung von Erkrankungen der Bronchien | |
| FI85142B (fi) | Foerfarande foer framstaellning av ergolinestrar. | |
| US4528299A (en) | 1-(2,3-Dimethyl-4-methoxyphenyl)-2-methyl-3-(1-pyrrolidinyl)-1-propanone and anti-spastic use thereof | |
| DE3844415A1 (de) | Neue 3-piperidincarboxaldehydoxim-derivate, deren herstellungsverfahren und deren verwendung als arzneimittel | |
| HU188170B (en) | Process for producing 3-square bracket-2-bracket-tetra-or hexahydro.4-pyridyl-bracket closed-ethyl-s uare bracket closed-indola derivatives | |
| CA1162544A (en) | Naphthyridine derivatives | |
| US4831049A (en) | Pyrrolizidine compounds, and their use as antiarrhythmic agents | |
| JP2577994B2 (ja) | 脳血流増加剤 | |
| HU186179B (en) | Process for preparing oxygen derivatives of 3,7-diaza-cyclophepta6j,k/fluorenes and pharmaceutical compositions contatining such compounds | |
| EP0462150B1 (de) | Neue aryloxy-alkylamine, deren herstellung und diese enthaltende arzneimittel |